Linaclotide · source year
4 selected, source-linked Linaclotide records carrying a 2024 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
3 represented types.
4 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01950403 at 2026-07-30T18:37:14.701Z. Its registry update date was 2024-12-09, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03471728 at 2026-07-30T18:39:33.779Z. Its registry update date was 2024-10-18, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 34 for the reviewed Linaclotide label family with a published date of 2024-07-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PubMed lists PMID 29184433 in International journal of general medicine as Journal Article, Review, with publication-date metadata of 2017-10-31 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗